Down-Regulation of miR-200c and Up-Regulation of miR-30c Target both Stemness and Metastasis Genes in Breast Cancer.
Metastasis
Self-Renewal
Spheroid
miR-200c
miR-30c
Journal
Cell journal
ISSN: 2228-5806
Titre abrégé: Cell J
Pays: Iran
ID NLM: 101566618
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
27
10
2018
accepted:
27
09
2018
entrez:
4
8
2019
pubmed:
4
8
2019
medline:
4
8
2019
Statut:
ppublish
Résumé
microRNAs (miRNAs) play important role in progression of tumorigenesis. They can target self-renewal and epithelial-mesenchymal transition (EMT) abilities in tumor cells, especially in cancer stem cells (CSCs). The objective of this study was to implement data mining to identify important miRNAs for targeting both self-renewal and EMT. We also aimed to evaluate these factors in mammospheres as model of breast cancer stem cells (BCSCs) and metastatic tumor tissues. In this experimental study, mammospheres were derived from MCF-7 cells and characterized for the CSCs properties. Then expression pattern of the selected miRNAs in spheroids were evaluated, using the breast tumor cells obtained from seven patients. Correlation of miRNAs with self-renewal and EMT candidate genes were assessed in mammospheres and metastatic tumors. The results showed that mammospheres represented more colonogenic and spheroid formation potential than MCF-7 cells (P<0.05). Additionally, they had enhanced migration and invasive capabilities. Our computational analyses determined that Simultaneous down-regulation and up-regulation of respectively
Identifiants
pubmed: 31376329
doi: 10.22074/cellj.2020.6406
pmc: PMC6722452
doi:
Types de publication
Journal Article
Langues
eng
Pagination
467-478Informations de copyright
Copyright© by Royan Institute. All rights reserved.
Déclaration de conflit d'intérêts
There is no conflict of interest in this study.
Références
J Breast Cancer. 2015 Dec;18(4):303-12
pubmed: 26770236
Oncogene. 2010 Jul 22;29(29):4194-204
pubmed: 20498642
Int J Clin Exp Pathol. 2017 Sep 01;10(9):10085-10091
pubmed: 31966899
PLoS One. 2010 Oct 04;5(10):
pubmed: 20957176
Stem Cell Reports. 2016 Jan 12;6(1):121-36
pubmed: 26771357
Trends Mol Med. 2014 Aug;20(8):460-9
pubmed: 25027972
J Clin Invest. 2014 Dec;124(12):5109-28
pubmed: 25401471
Cell. 2005 Jan 14;120(1):15-20
pubmed: 15652477
Cancer Cell Int. 2014 Aug 02;14:73
pubmed: 25120384
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Oncotarget. 2015 Mar 30;6(9):6472-98
pubmed: 25762624
Mol Cancer Ther. 2009 May;8(5):1055-66
pubmed: 19435871
Nat Commun. 2013;4:1393
pubmed: 23340433
J Oncol. 2015;2015:865816
pubmed: 25883654
Adv Drug Deliv Rev. 2015 Jan;81:53-61
pubmed: 25446141
PLoS One. 2016 Jan 15;11(1):e0145084
pubmed: 26771179
Nat Methods. 2015 Aug;12(8):697
pubmed: 26226356
Int J Oncol. 2007 Dec;31(6):1403-13
pubmed: 17982667
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Oncotarget. 2015 Oct 27;6(33):34968-78
pubmed: 26392416
PLoS One. 2012;7(11):e49987
pubmed: 23185507
Cancer Cell. 2011 Jul 12;20(1):104-18
pubmed: 21741600
Cell Cycle. 2010 Jul 15;9(14):2878-87
pubmed: 20581442
Science. 2009 Jun 26;324(5935):1670-3
pubmed: 19556499
J Thorac Dis. 2014 Jun;6(6):829-37
pubmed: 24977009
Oncogene. 2014 Jul 31;33(31):4077-88
pubmed: 24037528
Cell. 2009 Aug 7;138(3):592-603
pubmed: 19665978
Horm Cancer. 2010 Dec;1(6):306-19
pubmed: 21761362
Cancer. 2002 May 1;94(9):2511-6
pubmed: 12015777
Front Physiol. 2013 Aug 27;4:225
pubmed: 23986719
Am J Pathol. 2011 Jul;179(1):2-11
pubmed: 21640330
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2858-63
pubmed: 23386720
Breast Cancer Res Treat. 2013 Jan;137(2):373-82
pubmed: 23224145
Oncogene. 2015 Dec 3;34(49):5997-6006
pubmed: 25746005
J Cell Sci. 2013 May 15;126(Pt 10):2256-66
pubmed: 23525011
BMC Cancer. 2015 Sep 23;15:645
pubmed: 26400441
World J Stem Cells. 2015 Oct 26;7(9):1185-201
pubmed: 26516409
Nat Rev Genet. 2009 Oct;10(10):704-14
pubmed: 19763153
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787